RESUMEN
The aim of this study was to assess the effects of feeding immunized egg proteins (IEP) on the health and performance of newborn dairy calves. Sixty-four Holstein calves, both male and female, were divided over two treatments. Calves either received IEP or a placebo (PCB) in their colostrum and calf milk replacer (CMR) for the first 14 days of their life. Until day 49, CMR was offered at 15% of birth weight (BW), at 10% on days 49-57 and at 5% on days 57-63. In addition, calves received starter concentrate, chopped straw and water from 3 days old until 70 days old at the end of study. Individual CMR and concentrate intake were measured daily whilst BW was recorded weekly. Visual faecal scoring and health observations were conducted daily. Faecal samples were collected weekly up to 4 weeks and during the first 4 days of scouring to screen for presence of Cryptosporidium parvum, rotavirus, coronavirus, E. coli and Salmonella. Results indicated that feeding IEP increased BW (p < .05) at 42 and 56 days old, and BW also tended (p = .06) to be higher after weaning at 63-70 days old compared to the PCB group. When analysed using a repeated measures model, compared to feeding PCB, feeding IEP increased total concentrate consumption (p = .001) by 3.6kg/calf. Over the entire study, daily water intake was higher (p = .002) for the IEP group when compared with the PCB group. In the IEP group, 12 calves were scored as scouring whereas there were 14 calves in the PCB group. There were no significant differences between treatments in faecal pathogen load of neither healthy nor scouring calves. In conclusion, supplementing IEP during the first 14 days of calf life improved the performance of newborn calves. Further work is warranted to understand the mode of action of IEP in calves.
Asunto(s)
Enfermedades de los Bovinos/prevención & control , Diarrea/veterinaria , Proteínas del Huevo/inmunología , Alimentación Animal , Animales , Animales Recién Nacidos , Bovinos , Enfermedades de los Bovinos/epidemiología , Enfermedades de los Bovinos/inmunología , Diarrea/epidemiología , Diarrea/inmunología , Diarrea/prevención & control , Proteínas del Huevo/uso terapéutico , Heces/química , Heces/microbiología , Heces/parasitología , Femenino , Incidencia , Masculino , Aumento de PesoRESUMEN
We previously reported the results of a randomized, open-label trial of egg oral immunotherapy (OIT) in 50 children where 44% were desensitized and 46% were partially desensitized after 8 months of treatment. Here we focus on cell-mediated molecular mechanisms driving desensitization during egg OIT. We sought to determine whether changes in genome-wide gene expression in blood cells during egg OIT correlate with humoral responses and the clinical outcome. The blood cell transcriptome of 50 children receiving egg OIT was profiled using peripheral blood mononuclear cell (PBMC) samples obtained at baseline and after 3 and 8 months of OIT. We identified 467 differentially expressed genes (DEGs) after 3 or 8 months of egg OIT. At 8 months, 86% of the DEGs were downregulated and played a role in the signaling of TREM1, IL-6, and IL-17. In correlation analyses, Gal d 1-4-specific IgG4 antibodies associated positively with DEGs playing a role in pathogen recognition and antigen presentation and negatively with DEGs playing a role in the signaling of IL-10, IL-6, and IL-17. Desensitized and partially desensitized patients had differences in their antibody responses, and although most of the transcriptomic changes were shared, both groups had also specific patterns, which suggest slower changes in partially desensitized and activation of NK cells in the desensitized group. OIT for egg allergy in children inhibits inflammation and activates innate immune responses regardless of the clinical outcome at 8 months. Changes in gene expression patterns first appear as posttranslational protein modifications, followed by more sustained epigenetic gene regulatory functions related to successful desensitization.
Asunto(s)
Desensibilización Inmunológica , Hipersensibilidad al Huevo/terapia , Proteínas del Huevo/inmunología , Genómica/métodos , Inmunidad Innata , Inflamación/prevención & control , Leucocitos Mononucleares/metabolismo , Transcriptoma , Administración Oral , Adolescente , Alérgenos/administración & dosificación , Alérgenos/uso terapéutico , Especificidad de Anticuerpos , Niño , Citocinas/sangre , Relación Dosis-Respuesta Inmunológica , Hipersensibilidad al Huevo/sangre , Hipersensibilidad al Huevo/genética , Hipersensibilidad al Huevo/inmunología , Proteínas del Huevo/administración & dosificación , Proteínas del Huevo/efectos adversos , Proteínas del Huevo/uso terapéutico , Femenino , Regulación de la Expresión Génica , Ontología de Genes , Humanos , Inmunoglobulinas/sangre , Inflamación/etiología , Inflamación/inmunología , Isoanticuerpos/sangre , Isoanticuerpos/inmunología , Recuento de Linfocitos , Subgrupos Linfocitarios/inmunología , Masculino , Resultado del TratamientoRESUMEN
The transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor is an important mediator of nociception and its expression is enriched in nociceptive neurons. TRPV1 signaling has been implicated in bladder pain and is a potential analgesic target. Resiniferatoxin is the most potent known agonist of TRPV1. Acute exposure of the rat bladder to resiniferatoxin has been demonstrated to result in pain-related freezing and licking behaviors that are alleviated by virally encoded IL-4. The interleukin-4-inducing principle of Schistosoma mansoni eggs (IPSE) is a powerful inducer of IL-4 secretion, and is also known to alter host cell transcription through a nuclear localization sequence-based mechanism. We previously reported that IPSE ameliorates ifosfamide-induced bladder pain in an IL-4- and nuclear localization sequence-dependent manner. We hypothesized that pre-administration of IPSE to resiniferatoxin-challenged mice would dampen pain-related behaviors. IPSE indeed lessened resiniferatoxin-triggered freezing behaviors in mice. This was a nuclear localization sequence-dependent phenomenon, since administration of a nuclear localization sequence mutant version of IPSE abrogated IPSE's analgesic effect. In contrast, IPSE's analgesic effect did not seem IL-4-dependent, since use of anti-IL-4 antibody in mice given both IPSE and resiniferatoxin did not significantly affect freezing behaviors. RNA-Seq analysis of resiniferatoxin- and IPSE-exposed bladders revealed differential expression of TNF/NF-κb-related signaling pathway genes. In vitro testing of IPSE uptake by urothelial cells and TRPV1-expressing neuronal cells showed uptake by both cell types. Thus, IPSE's nuclear localization sequence-dependent therapeutic effects on TRPV1-mediated bladder pain may act on TRPV1-expressing neurons and/or may rely upon urothelial mechanisms.
Asunto(s)
Diterpenos/efectos adversos , Proteínas del Huevo/uso terapéutico , Proteínas del Helminto/uso terapéutico , Interacciones Huésped-Parásitos/inmunología , Factores Inmunológicos/uso terapéutico , Dolor/tratamiento farmacológico , Parásitos/química , Vejiga Urinaria/patología , Animales , Núcleo Celular/efectos de los fármacos , Núcleo Celular/metabolismo , Proteínas del Huevo/farmacología , Endocitosis/efectos de los fármacos , Femenino , Perfilación de la Expresión Génica , Regulación de la Expresión Génica/efectos de los fármacos , Proteínas del Helminto/farmacología , Humanos , Factores Inmunológicos/farmacología , Interleucina-4/metabolismo , Ratones Endogámicos C57BL , FN-kappa B/metabolismo , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Señales de Localización Nuclear/metabolismo , Dolor/genética , Análisis de Componente Principal , Transporte de Proteínas/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Factor de Necrosis Tumoral alfa/metabolismo , Vejiga Urinaria/efectos de los fármacos , Urotelio/metabolismoRESUMEN
PURPOSE: Despite its many health benefits, moderate exercise can induce joint discomfort when done infrequently or too intensely even in individuals with healthy joints. This study was designed to evaluate whether NEM® (natural eggshell membrane) would reduce exercise-induced cartilage turnover or alleviate joint pain or stiffness, either directly following exercise or 12 hours post exercise, versus placebo. PATIENTS AND METHODS: Sixty healthy, postmenopausal women were randomly assigned to receive either oral NEM 500 mg (n=30) or placebo (n=30) once daily for two consecutive weeks while performing an exercise regimen (50-100 steps per leg) on alternating days. The primary endpoint was any statistically significant reduction in exercise-induced cartilage turnover via the biomarker C-terminal cross-linked telopeptide of type-II collagen (CTX-II) versus placebo, evaluated at 1 and 2 weeks of treatment. Secondary endpoints were any reductions in either exercise-induced joint pain or stiffness versus placebo, evaluated daily via participant questionnaire. The clinical assessment was performed on the per protocol population. RESULTS: NEM produced a significant absolute treatment effect (TEabs) versus placebo for CTX-II after both 1 week (TEabs -17.2%, P=0.002) and 2 weeks of exercise (TEabs -9.9%, P=0.042). Immediate pain was not significantly different; however, rapid treatment responses were observed for immediate stiffness (Day 7) and recovery pain (Day 8) and recovery stiffness (Day 4). No serious adverse events occurred and the treatment was reported to be well tolerated by study participants. CONCLUSION: NEM rapidly improved recovery from exercise-induced joint pain (Day 8) and stiffness (Day 4) and reduced discomfort immediately following exercise (stiffness, Day 7). Moreover, a substantial chondroprotective effect was demonstrated via a decrease in the cartilage degradation biomarker CTX-II. Clinical Trial Registration number: NCT02751944.
Asunto(s)
Artralgia/prevención & control , Suplementos Dietéticos , Proteínas del Huevo/uso terapéutico , Cáscara de Huevo , Posmenopausia , Animales , Biomarcadores , Colágeno Tipo II/uso terapéutico , Femenino , Voluntarios Sanos , Humanos , Persona de Mediana Edad , Dolor/tratamiento farmacológicoRESUMEN
BACKGROUND: We evaluated the safety and efficacy of low-egg-allergen cookies (LAC) as low-dose oral immunotherapy (OIT) in children with severe egg allergy. We also examined the relationship between mild desensitization by low-dose OIT and serum biomarkers of allergy. METHODS: We enrolled 13 children with egg allergy who could not receive OIT with hard-boiled egg white (EW). For 11 participants, OIT was carried out using LAC for 3-4 months. Open food challenges with hard-boiled EW and blood samplings were performed before and after OIT. Participants were divided into 2 groups: high effect (H-E) and no/low effect (N/L-E). Serum levels of total IgE and egg yolk-, EW-, and ovomucoid (OM)-specific IgE, ovalbumin (OVA)- and OM-specific IgG4, IgA1, and IgA2, and the percentage of CD 203c+ were measured. RESULTS: Allergic severity was reduced in 7 patients, who were assigned to the H-E group. Moreover, no study participants were taken off the intake of LAC during OIT. In the H-E group, OVA-specific IgA2 levels after OIT were significantly higher than before OIT. The ratios of OM-specific IgG4/OM-specific IgE and OM-specific IgA2/OM-specific IgE in the H-E group after OIT were significantly higher than before OIT. CONCLUSION: Our findings suggest that low-dose OIT using LAC is an effective and safe treatment for patients with severe egg allergy.
Asunto(s)
Alérgenos/uso terapéutico , Desensibilización Inmunológica/métodos , Hipersensibilidad al Huevo/terapia , Proteínas del Huevo/inmunología , Huevos , Administración Oral , Alérgenos/inmunología , Niño , Preescolar , Estudios Transversales , Ingestión de Alimentos , Hipersensibilidad al Huevo/inmunología , Proteínas del Huevo/uso terapéutico , Femenino , Humanos , Inmunoglobulina E/sangre , Masculino , Resultado del TratamientoAsunto(s)
Alérgenos/uso terapéutico , Desensibilización Inmunológica/métodos , Hipersensibilidad al Huevo/terapia , Proteínas del Huevo/uso terapéutico , Proteínas de la Leche/uso terapéutico , Administración Oral , Alérgenos/inmunología , Animales , Culinaria , Hipersensibilidad al Huevo/inmunología , Proteínas del Huevo/inmunología , Calor , Humanos , Proteínas de la Leche/inmunologíaRESUMEN
The accelerating search for new types of drugs and delivery strategies poses challenge to understanding the mechanism of delivery. To this end, a detailed atomistic picture of binding between the drug and carrier is quintessential. Although many studies focus on the electrostatics of drug-vector interactions, it has also been pointed out that entropic factors relating to water and counterions can play an important role. By carrying out extensive molecular dynamics simulations and subsequently validating with experiments, we shed light herein on the binding in aqueous solution between a protein drug and polymeric carrier. We examined the complexation between the polymer poly(ethylene glycol) methyl ether acrylate-b-poly(carboxyethyl acrylate (PEGMEA-b-PCEA) and the protein egg white lysozyme, a system that acts as a model for polymer-vector/protein-drug delivery systems. The complexation has been visualized and characterized using contact maps and hydrogen bonding analyses for five independent simulations of the complex, each running over 100 ns. Binding at physiological pH is, as expected, mediated by Coulombic attraction between the positively charged protein and negatively charged carboxylate groups on the polymer. However, we find that consideration of electrostatics alone is insufficient to explain the complexation behavior at low pH. Intracomplex hydrogen bonds, van der Waals interactions, as well as water-water interactions dictate that the polymer does not release the protein at pH 4.8 or indeed at pH 3.2 even though the Coulombic attractions are largely removed as carboxylate groups on the polymer become titrated. Experiments in aqueous solution carried out at pH 7.0, 4.5, and 3.0 confirm the veracity of the computed binding behavior. Overall, these combined simulation and experimental results illustrate that coulomb interactions need to be complemented with consideration of other entropic forces, mediated by van der Waals interactions and hydrogen bonding, to search for adequate descriptors to predict binding and release properties of polymer-protein complexes. Advances in computational power over the past decade make atomistic molecular dynamics simulations such as implemented here one of the few avenues currently available to elucidate the complexity of these interactions and provide insights toward finding adequate descriptors. Thus, there remains much room for improvement of design principles for efficient capture and release delivery systems.
Asunto(s)
Sistemas de Liberación de Medicamentos , Proteínas del Huevo/química , Muramidasa/química , Polímeros/química , Proteínas del Huevo/uso terapéutico , Entropía , Humanos , Enlace de Hidrógeno , Concentración de Iones de Hidrógeno , Simulación de Dinámica Molecular , Muramidasa/uso terapéutico , Preparaciones Farmacéuticas/química , Polietilenglicoles/química , Polímeros/uso terapéutico , Termodinámica , Agua/químicaRESUMEN
INTRODUCTION: Cow's milk and egg are the most frequent causes of food allergy in the first years of life. Treatments such as oral immunotherapy (OIT) have been investigated as an alternative to avoidance diets. No clinical practice guides on the management of OIT with milk and egg are currently available. OBJECTIVES: To develop a clinical guide on OIT based on the available scientific evidence and the opinions of experts. METHODS: A review was made of studies published in the period between 1984 and June 2016, Doctoral Theses published in Spain, and summaries of communications at congresses (SEAIC, SEICAP, EAACI, AAAAI), with evaluation of the opinion consensus established by a group of experts pertaining to the scientific societies SEICAP and SEAIC. RESULTS: Recommendations have been established regarding the indications, requirements and practical aspects of the different phases of OIT, as well as special protocols for patients at high risk of suffering adverse reactions. CONCLUSIONS: A clinical practice guide is presented for the management of OIT with milk and egg, based on the opinion consensus of Spanish experts.
Asunto(s)
Alérgenos/uso terapéutico , Desensibilización Inmunológica/métodos , Proteínas del Huevo/uso terapéutico , Hipersensibilidad a los Alimentos/terapia , Proteínas de la Leche/uso terapéutico , Administración Oral , Alérgenos/inmunología , Protocolos Clínicos , Cálculo de Dosificación de Drogas , Proteínas del Huevo/inmunología , Testimonio de Experto , Hipersensibilidad a los Alimentos/inmunología , Humanos , Proteínas de la Leche/inmunología , Guías de Práctica Clínica como Asunto , EspañaRESUMEN
INTRODUCTION: Cow's milk and egg are the most frequent causes of food allergy in the first years of life. Treatments such as oral immunotherapy (OIT) have been investigated as an alternative to avoidance diets. No clinical practice guides on the management of OIT with milk and egg are currently available. OBJECTIVES: To develop a clinical guide on OIT based on the available scientific evidence and the opinions of experts. METHODS: A review was made of studies published in the period between 1984 and June 2016, Doctoral Theses published in Spain, and summaries of communications at congresses (SEAIC, SEICAP, EAACI, AAAAI), with evaluation of the opinion consensus established by a group of experts pertaining to the scientific societies SEICAP and SEAIC. RESULTS: Recommendations have been established regarding the indications, requirements and practical aspects of the different phases of OIT, as well as special protocols for patients at high risk of suffering adverse reactions. CONCLUSIONS: A clinical practice guide is presented for the management of OIT with milk and egg, based on the opinion consensus of Spanish experts.
Asunto(s)
Alérgenos/uso terapéutico , Desensibilización Inmunológica/métodos , Hipersensibilidad al Huevo/terapia , Proteínas del Huevo/uso terapéutico , Hipersensibilidad a la Leche/terapia , Proteínas de la Leche/uso terapéutico , Administración Oral , Alérgenos/inmunología , Animales , Bovinos , Contraindicaciones , Hipersensibilidad al Huevo/inmunología , Proteínas del Huevo/inmunología , Testimonio de Experto , Humanos , Tolerancia Inmunológica , Hipersensibilidad a la Leche/inmunología , Proteínas de la Leche/inmunología , Guías de Práctica Clínica como Asunto , EspañaRESUMEN
BACKGROUND: The present study aimed to investigate the in vivo antihypertensive effect on spontaneously hypertensive rats (SHRs) induced by egg protein-derived peptide QIGLF, which has been previously characterized in vitro as a potent angiotensin-converting enzyme inhibitor. RESULTS: In vivo antihypertensive effect of QIGLF orally administered was evaluated by the tail-cuff method. The systolic blood pressure and the diastolic blood pressure of rats were measured 0, 5, 10, 15 and 20 h after administration every day. Subsequently, the effect of QIGLF on angiotensin-converting enzyme mRNA expression in the kidney of SHRs was evaluated by a polymerase chain reaction. Systolic blood pressure was found to be reduced markedly in the SHRs after a single oral administration. CONCLUSION: The results show that the effect of QIGLF (50 mg kg-1 body weight) was similar to that of captopril (10 mg kg-1 body weight) with respect to lowering systolic blood pressure in SHRs. Therefore, egg white protein-derived peptide QIGLF may be useful in the prevention or treatment of hypertension. © 2016 Society of Chemical Industry.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Antihipertensivos/uso terapéutico , Suplementos Dietéticos , Proteínas del Huevo/uso terapéutico , Hipertensión/dietoterapia , Riñón/fisiopatología , Oligopéptidos/uso terapéutico , Fragmentos de Péptidos/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Animales , Antihipertensivos/administración & dosificación , Antihipertensivos/efectos adversos , Presión Sanguínea/efectos de los fármacos , Captopril/efectos adversos , Captopril/uso terapéutico , Suplementos Dietéticos/efectos adversos , Proteínas del Huevo/administración & dosificación , Proteínas del Huevo/efectos adversos , Represión Enzimática , Hipertensión/tratamiento farmacológico , Hipertensión/metabolismo , Hipertensión/fisiopatología , Riñón/metabolismo , Masculino , Oligopéptidos/administración & dosificación , Oligopéptidos/efectos adversos , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/efectos adversos , Peptidil-Dipeptidasa A/química , Peptidil-Dipeptidasa A/genética , Peptidil-Dipeptidasa A/metabolismo , ARN Mensajero/metabolismo , Ratas Endogámicas SHR , Ratas Wistar , Reacción en Cadena en Tiempo Real de la Polimerasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de TiempoRESUMEN
PURPOSE OF REVIEW: Until recently, nutritional guidelines did not support early introduction of allergenic foods into the diet of high-risk infants. Following recent studies, this approach is beginning to change, at least for peanuts. This review will examine the change in nutritional guidelines and the scientific data that led to these changes. RECENT FINDING: In a recent prospective controlled study, regular consumption of peanut protein in infants from 4-11 months of age with atopic dermatitis or egg allergy, was associated with lower prevalence of peanut allergy (1.9%) at 60 months of age compared with peanut avoidance (13.7%). Other studies demonstrated that earlier introduction of cow's milk protein and egg powder were also associated with decreased risk for milk and egg allergy, respectively. SUMMARY: Recent studies suggest that early rather than late introduction of allergenic foods reduces the risk of food allergy. The preferred timing of food introduction might be sooner than the current recommendation, and might apply not only to high-risk infants.
Asunto(s)
Alérgenos/uso terapéutico , Anafilaxia/prevención & control , Proteínas del Huevo/uso terapéutico , Hipersensibilidad a los Alimentos/dietoterapia , Proteínas de la Leche/uso terapéutico , Alérgenos/inmunología , Anafilaxia/etiología , Animales , Bovinos , Preescolar , Dietoterapia , Proteínas del Huevo/inmunología , Hipersensibilidad a los Alimentos/complicaciones , Humanos , Lactante , Proteínas de la Leche/inmunología , Política Nutricional/tendenciasRESUMEN
BACKGROUND AND PURPOSE: There is an inverse association between dairy food consumption and the incidence of stroke in observational studies. However, it is unknown whether the relationship is causal or, if so, what components in milk are responsible for reducing the incidence of stroke. METHODS: Stroke-prone spontaneously hypertensive rats were fed diets comprising amino acids, proteins from different sources (casein, whey, soybean, or egg white), or fats from different sources (butter, beef tallow, or cocoa butter) and the onset of stroke and lifespan were examined. RESULTS: Increasing the amount of dietary casein (5% to 55% of caloric intake) markedly delayed the onset of stroke. However, when stroke-prone spontaneously hypertensive rats were fed diets containing 55% of caloric intake as protein, rats fed casein or whey protein, a major component of milk, displayed a delayed onset of stroke compared with rats fed soybean or egg white protein. Rats fed an amino acids diet containing the same amino acids composition as casein did not have a delay in the onset of stroke. Increasing dietary fats, including butter as well as beef tallow and cocoa butter, did not affect the onset of stroke. All diets did not affect blood pressure in the early stage. CONCLUSIONS: These data suggest that the inverse association between dairy food consumption and incidence of stroke in epidemiological studies is causal and that peptides in milk protein, but not fat, might be responsible for this effect.
Asunto(s)
Proteínas de la Leche/uso terapéutico , Accidente Cerebrovascular/prevención & control , Aminoácidos/farmacología , Animales , Presión Sanguínea/fisiología , Mantequilla , Caseínas/uso terapéutico , Hemorragia Cerebral/dietoterapia , Hemorragia Cerebral/patología , Hemorragia Cerebral/prevención & control , Infarto Cerebral/dietoterapia , Infarto Cerebral/patología , Infarto Cerebral/prevención & control , Dieta , Grasas de la Dieta/farmacología , Proteínas del Huevo/uso terapéutico , Masculino , Ratas , Ratas Endogámicas SHR , Proteínas de Soja/uso terapéutico , Glycine max/química , Accidente Cerebrovascular/dietoterapia , Accidente Cerebrovascular/patología , Urea/farmacología , Proteína de Suero de LecheRESUMEN
There is no approved therapy for food allergy. The current standard of care is elimination of the triggering food from the diet and accessibility to epinephrine. Immunotherapy is a promising treatment approach. While desensitization to most foods seems feasible, it remains unclear if a permanent state of tolerance is achievable. The research team at Duke is pioneering immunotherapy for food allergies. Work here has evolved over time from small open-label pilot studies to larger randomized designs. Our data show that immunological changes associated with immunotherapy include reduction in mast cell reactivity, decreased basophil responses, decreased specific-immunoglobulin (Ig)E, increased IgG4 and induction of regulatory T cells. Immunotherapy has generated much excitement in the food allergy community; however, further studies are needed before it is ready for clinical use.
Asunto(s)
Desensibilización Inmunológica , Hipersensibilidad a los Alimentos/terapia , Administración Oral , Administración Sublingual , Alérgenos/administración & dosificación , Alérgenos/uso terapéutico , Arachis/efectos adversos , Arachis/inmunología , Basófilos/inmunología , Desensibilización Inmunológica/métodos , Método Doble Ciego , Proteínas del Huevo/efectos adversos , Proteínas del Huevo/uso terapéutico , Epinefrina/uso terapéutico , Hipersensibilidad a los Alimentos/dietoterapia , Hipersensibilidad a los Alimentos/tratamiento farmacológico , Humanos , Tolerancia Inmunológica , Inmunoglobulina E/inmunología , Inmunoglobulina G/inmunología , Inyecciones Subcutáneas , Mastocitos/inmunología , Hipersensibilidad a la Leche/terapia , Proteínas de la Leche/efectos adversos , Proteínas de la Leche/uso terapéutico , Hipersensibilidad a la Nuez/terapia , Proyectos Piloto , Ensayos Clínicos Controlados Aleatorios como Asunto , Linfocitos T Reguladores/inmunologíaRESUMEN
Dietary proteins can influence colonic carcinogenesis; some proteins have a promotional effect, whereas others exhibit a preventive effect. Dietary egg yolk proteins have been reported to suppress the expression of colon tumors in rats. In this study, we investigated the effect of consumption egg yolk proteins on cell proliferation in a rat model of azoxymethane (AOM)-induced colon cancer. We hypothesize, based on the literature of egg yolk protein actions, that they protect against colon tumor development. Therefore, male F344 rats were fed a purified AIN-93G diet containing either 20% casein (control) or 20% egg yolk proteins for 5 weeks. After 1 week on the experimental diet, the rats were administered weekly subcutaneous injections of saline or AOM for 2 weeks to induce aberrant crypt foci. Rats were administered an intraperitoneal injection of 5-bromo-2'-deoxyuridine 1 hour before being euthanized for examination of DNA synthesis in the colonic mucosa. The contents of the cecum were analyzed for the presence of short-chain fatty acids (SCFAs). In the AOM-injected rats, the yolk protein diet suppressed aberrant crypt foci formation and reduced the proliferative 5-bromo-2'-deoxyuridine-labeling index in the proximal colon when compared with the control diet. A significant increase in cecal SCFAs was observed in the rats that were fed egg yolk proteins. These results indicate that dietary egg yolk proteins have a preventive effect on AOM-induced large bowel carcinogenesis in rats; it exerts this effect by altering cell proliferation through SCFA production. This study suggests that the consumption of egg yolk proteins might be protective against colon carcinogenesis.
Asunto(s)
Anticarcinógenos/uso terapéutico , Proliferación Celular/efectos de los fármacos , Colon/efectos de los fármacos , Neoplasias del Colon/prevención & control , Proteínas del Huevo/uso terapéutico , Ácidos Grasos Volátiles/metabolismo , Lesiones Precancerosas/dietoterapia , Animales , Anticarcinógenos/farmacología , Azoximetano/efectos adversos , Bromodesoxiuridina/metabolismo , Carcinógenos , Caseínas/farmacología , Ciego/efectos de los fármacos , Ciego/fisiopatología , Colon/patología , ADN/biosíntesis , Proteínas del Huevo/farmacología , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/patología , Masculino , Ratas , Ratas Endogámicas F344RESUMEN
Algunos fragmentos de proteínas alimentarias, una vez liberados mediante hidrólisis, pueden producir un descenso del tono arterial. Son importantes los hidrolizados y péptidos provenientes de proteínas lácteas. Destacan los hidrolizados de caseína con tripsina, y los productos antihipertensivos obtenidos por fermentación de la leche con Lactobacillus helveticus. Estos productos contienen secuencias como Val-Pro-Pro (VPP) e Ile-Pro-Pro (IPP), que inhiben la enzima convertidor a de la angiotensina (ECA). Algunas cepas de Enterococcus faecalis también producen péptidos antihipertensivos inhibidores de la ECA. Entre estos péptidos destaca la secuencia LHLPLP. Existen asimismo péptidos e hidrolizados antihipertensivos derivados de proteínas de huevo. Podemos citar las secuencias FRADHPFL (ovokinina) y RADHPF (ovokinina 2-7) con actividad vasodilatadora endotelio-dependiente, y algunos hidrolizados de clara de huevo que inhibenla ECA. Los productos mencionados podrían utilizarse como ingredientes en alimentos funcionales. Algunos han probado ya su eficacia y seguridad en pacientes hipertensos
Antihypertensive hydrolysates and peptides have been isolated from food proteins. Among them, there are of particular interest the antihypertensive casein hydrolysates, and some antihypertensive products obtained when milk was fermented by Lactobacillus helveticus. The sequences Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), with angiotensin- converting enzyme (ACE) inhibitory activity, have been isolated from these fermented products. Selected Enterococcus faecalis strains can also produce milk derived peptides with ACE inhibitory and antihypertensive activities. The main of them is the sequence LHLPLP. Some studies also describe the production of antihypertensive hydrolysates and peptides from egg proteins. The sequences FRADHPFL (ovokinin) and RADHPFL (ovokinin 2-7),that have shown endothelium-dependent vasodilator activity, were obtained at first. Some egg white hydrolysates with ACE inhibitory activity have also been described. The idea of including the abovementioned products as functional food ingredients is particularly attractive. Some of them have already proved their safety and effectiveness in hypertensive patients
Asunto(s)
Humanos , Antihipertensivos/análisis , Péptidos/uso terapéutico , Hipertensión/dietoterapia , Proteínas del Huevo/uso terapéutico , Proteínas de la Leche/uso terapéutico , Peptidil-Dipeptidasa A/farmacocinéticaRESUMEN
We determined the effects of yolk water-soluble protein (YSP) on bone resorption. YSP potently suppressed osteoclastogenesis from bone marrow-derived precursor cells driven by tumor necrosis factor-alpha (TNF-alpha). YSP (200 microg/ml) abolished the formation of tartarate-resistant acid phosphatase (TRAP)-positive osteoclasts. Furthermore, TNF-alpha induced TRAP activity was greatly inhibited by YSP (100 microg/ml) treatment. Our results suggest that YSP has therapeutic potential for bone-erosive diseases.
Asunto(s)
Resorción Ósea/prevención & control , Proteínas del Huevo/farmacología , Fosfatasa Ácida/metabolismo , Animales , Resorción Ósea/tratamiento farmacológico , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Proteínas del Huevo/uso terapéutico , Isoenzimas/metabolismo , Masculino , Ratones , Osteoclastos/citología , Osteoporosis/tratamiento farmacológico , Fosfatasa Ácida TartratorresistenteRESUMEN
BACKGROUND: Autoimmune ovarian disease (AOD) caused by auto-reactive T cells is considered a major reason for human premature ovarian failure, which affects 5% of women worldwide. METHODS AND RESULTS: To develop an effective treatment for AOD, we showed that the co-administration of mouse zona pellucida protein 3 (mZP3) protein and DNA vaccine encoding the mZP3 was able to meliorate AOD in an AOD murine model induced by the mZP3. We observed that established AOD in mice reverted to a normal ovarian morphology without notable T-cell infiltration in the co-administrated group; whereas mice in the control groups developed severe AOD. The amelioration appears to be antigen specific because other co-administration combinations failed to reverse AOD and correlates with significant reductions of pathogenic T-cell responses and productions of tumor necrosis factor-alpha and interferon-gamma. Furthermore, the melioration is apparently associated with the induction of mZP3 specific regulatory T cells that exhibit a phenotypic CD4(+)CD25(-)FoxP3(+)IL-10(+) in the co-administrated group, which can be transferred to reverse AOD in vivo. CONCLUSIONS: Thus, co-administration of mZP3 DNA and protein vaccines can be used to treat established AOD, and may provide a novel immunotherapy strategy to treat other autoimmune diseases.
Asunto(s)
Enfermedades Autoinmunes/tratamiento farmacológico , Proteínas del Huevo/uso terapéutico , Inmunoterapia/métodos , Glicoproteínas de Membrana/uso terapéutico , Enfermedades del Ovario/tratamiento farmacológico , Receptores de Superficie Celular/uso terapéutico , Vacunas de ADN/uso terapéutico , Animales , Anticuerpos Monoclonales , Enfermedades Autoinmunes/inmunología , Proliferación Celular , Cartilla de ADN/genética , Proteínas del Huevo/administración & dosificación , Femenino , Citometría de Flujo , Glicoproteínas de Membrana/administración & dosificación , Ratones , Enfermedades del Ovario/inmunología , Receptores de Superficie Celular/administración & dosificación , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Linfocitos T/citología , Linfocitos T/inmunología , Vacunas de ADN/inmunología , Glicoproteínas de la Zona PelúcidaRESUMEN
Egg is the largest biological cell known which originates from one cell division and is composed of various important chemical substances that form the basis of life. The avian egg is an important source of nutrients, containing all of the proteins, lipids, vitamins, minerals and growth factors required by the developing embryo, as well as a number of defence factors to protect against bacterial and viral infection. This review mainly focuses on biological activities of proteins and peptides derived from egg components. Several biological activities have now been associated with egg components, including novel anti-microbial activities, anti-adhesive properties, immunomodulatory, anti-cancer, and anti-hypertensive activities, anti-oxidant properties, protease inhibitors, nutrient bioavailability and functional lipids, highlighting the importance of egg and egg components in human health, and disease prevention and treatment.